Results 11 to 20 of about 684,663 (243)

PD-L1 Expression in Mastocytosis [PDF]

International Journal of Molecular Sciences, 2019
Programmed death 1 (PD-1), when activated by its ligands PD-L1 and PD-L2, suppresses active immune cells in normal immune regulation to limit autoimmunity and, in tumors, as a mechanism of immune evasion. PD-L1 expression has been described as both a prognostic and predictive marker in many solid and hematologic neoplasms, as targeted therapies against
Margaret Williams, Diane S. Lidke, Karin Hartmann, Tracy I. George   +3 more
openaire   +3 more sources

PD-L1-Targeted Radionuclide Therapy Combined with αPD-L1 Antibody Immunotherapy Synergistically Improves the Antitumor Effect

, 2022
Immune checkpoint blockers (ICBs) targeting programmed death receptor 1 (PD-1) ligand 1 (PD-L1) for immunotherapy have radically reformed oncology. It is of great significance to enhance the response rate of ICB in cancer patients. Here, a radioiodinated
Yiren Zhang (1760983), Zhide Guo (1424674), Xueyuan Zeng (12728985), Jinxiong Huang (11276730), Xuejun Wen (349183), Xianzhong Zhang (1424671), Yesen Li (4430377), Haojun Chen (3727810), Jia Liu (41593), Xinying Zeng (6627383), Xingxing Cheng (4164958), Xiaoyuan Chen (322516)   +11 more
core   +1 more source

PD-L1 degradation is regulated by electrostatic membrane association of its cytoplasmic domain

Nature Communications, 2021
The cytoplasmic domain of PD-L1 (PD-L1-CD) is involved in regulating PD-L1 stability and degradation. Here the authors show that membrane binding of PD-L1-CD mediates the cellular levels of PD-L1, while metformin can disrupt the interaction between PD-L1-
Maorong Wen, Yunlei Cao, Bin Wu, Taoran Xiao, Ruiyu Cao, Qian Wang, Xiwei Liu, Hongjuan Xue, Yang Yu, Jialing Lin, Chenqi Xu, Jie Xu, Bo OuYang   +12 more
doaj   +1 more source

Programmed Death-Ligand 1 Expression in Lymphovascular Tumor Emboli in Lung Cancer

JTO Clinical and Research Reports, 2022
Introduction: Programmed death-ligand 1 (PD-L1) expression determined by immunohistochemistry is the most widely used biomarker for predicting response to immune checkpoint inhibitors.
Yi-Chen Yeh, MD, Hsiu-Hsun Ma, MS, Ping-Yuan Chu, MS, Hsiang-Ling Ho, PhD, Teh-Ying Chou, MD, PhD   +4 more
doaj   +1 more source

PD-L1-Expressing Extracellular Vesicles for the Treatment of Pneumonia

, 2023
Acute respiratory distress syndrome (ARDS) is a severe lung condition with a high mortality rate and a lack of effective drug therapy. In this work, we developed mesenchymal stem cell (MSC)-derived extracellular vesicles with high PD-L1 expression (MSC ...
Ting Lu (149031), Fang Xu (138747), Qingle Ma (10801724), Huaxing Dai (10801718), Heng Wang (76752), Yi Wu (197719), Chenlu Yao (17175038), Anning Song (17175035), Xiaoyu Wang (182979), Jialu Xu (8485347), Chao Wang (146527)   +10 more
core   +1 more source

Small-molecule PD-L1 inhibitor BMS1166 abrogates the function of PD-L1 by blocking its ER export

OncoImmunology, 2020
Therapeutic monoclonal antibodies against the PD-L1/PD-1 (programmed death ligand-1/programmed cell death protein-1) axis have achieved great successes in cancer treatments, but the development of small-molecule immunomodulators of the pathway has lagged
Fang-Fang Chen, Zheng Li, Dawei Ma, Qiang Yu   +3 more
doaj   +1 more source

PD-1/PD-L1 blockade accelerates the progression of atherosclerosis in cancer patients

, 2022
PD-1(programed death-1)/PD-L1(programed death-1 ligand) blockade represents a major breakthrough of anti-cancer therapies, however, it may come with increased risk of cardiovascular morbidity, such as myocarditis, acute coronary syndrome, arrhythmias ...
Tse, Gary, Lin, Chen, Dong, Mei, Liu, Tong, Zhang, Nan, Lin, Zerun, Zhong, Lin, Yu, Ting, Wang, Rujian   +8 more
core   +1 more source

PD‐L1 methylation regulates PD‐L1 expression and is associated with melanoma survival [PDF]

Pigment Cell & Melanoma Research, 2018
AbstractThe aim of this study is to determine the significance of programmed death ligand 1 (PD‐L1 or CD274) methylation in relation to PD‐L1 expression and survival in melanoma. Despite the clinical importance of therapies targeting the PD‐1/PD‐L1 immune checkpoint in melanoma, factors regulating PD‐L1 expression, including epigenetic mechanisms, are ...
Goran Micevic, Durga Thakral, Meaghan McGeary, Marcus W. Bosenberg   +3 more
openaire   +2 more sources

Cerenkov luminescence imaging is an effective preclinical tool for assessing colorectal cancer PD-L1 levels in vivo

EJNMMI Research, 2020
Background Preclinical and clinical studies have demonstrated that immunotherapy has effectively delayed tumor progression, and the clinical outcomes of anti-PD-1/PD-L1 therapy were related to PD-L1 expression level in the tumors.
Sheng Zhao, Wenbin Pan, Huijie Jiang, Rongjun Zhang, Hao Jiang, Zonghui Liang, Hongbo Hu   +6 more
doaj   +1 more source

PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy

Cancer Medicine, 2020
Background Intravascular large B‐cell lymphoma (IVLBCL) is a rare form of diffuse large B‐cell lymphoma (DLBCL) arising in extranodal sites. PD‐L1 expression of tumor cells has been reported in IVLBCL cells, but its clinicopathological relevance remains ...
Yuka Suzuki, Kei Kohno, Kosei Matsue, Ayako Sakakibara, Eri Ishikawa, Satoko Shimada, Kazuyuki Shimada, Seiyo Mabuchi, Taishi Takahara, Seiichi Kato, Shigeo Nakamura, Akira Satou   +11 more
doaj   +1 more source